# Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

> **NCT06900543** · PHASE3 · RECRUITING · sponsor: **Chengdu New Radiomedicine Technology Co. LTD.** · enrollment: 108 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** NRT6003 Injection
- **DRUG:** cTACE

## Key facts

- **NCT ID:** NCT06900543
- **Lead sponsor:** Chengdu New Radiomedicine Technology Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06900543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06900543, "Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06900543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*